Advanced search
Publication Cover
Pain Management Volume 13, 2023 - Issue 8
Submit an article Journal homepage
783
Views
0
CrossRef citations to date
0
Altmetric
Short Communication

Temporal Analysis of Remote Electric Neuromodulation for The Prevention of Migraine

Andrew M Blumenfeld1 The Los Angeles Headache Center, Los Angeles, CA90067, USA;2 San Diego Headache Center, San Diego, CA92111, USAView further author information
,
Liron Rabany3 Theranica Bio-Electronics, Netnaya, 4250438, IsraelCorrespondence[email protected]
View further author information
,
Alon Ironi3 Theranica Bio-Electronics, Netnaya, 4250438, IsraelView further author information
,
Alit Stark-Inbar3 Theranica Bio-Electronics, Netnaya, 4250438, IsraelView further author information
,
Dagan Harris3 Theranica Bio-Electronics, Netnaya, 4250438, IsraelView further author information
,
Rashmi B Halker Singh4 Mayo Clinic, Scottsdale, AZ85259, USAView further author information
&
Andrea M Harriott5 Massachusetts General Hospital, Boston, MA 02114, USAView further author information
 show all
Pages 425-432 | Received 09 Apr 2023, Accepted 28 Jul 2023, Published online: 24 Aug 2023

References

  • Wilbanks C . Migraine in Adult Primary Care. J. Nurse Pract.18(4), 366–369 (2022).
  • Ong JJY , WeiDY-T , GoadsbyPJ. Recent Advances in Pharmacotherapy for Migraine Prevention: From Pathophysiology to New Drugs. Drugs78(4), 411–437 (2018).
  • The American Headache Society Position Statement On Integrating New Migraine Treatments Into Clinical Practice. Headache J. Head Face Pain59(1), 1–18 (2019).
  • Ashina M , BuseDC , AshinaHet al. Migraine: integrated approaches to clinical management and emerging treatments. Lancet397(10283), 1505–1518 (2021).
  • Ailani J , WinnerP , HartryAet al. Patient preference for early onset of efficacy of preventive migraine treatments. Headache J. Head Face Pain62(3), 374–382 (2022).
  • Schwedt TJ , MartinA , KymesSet al. Patient preferences for attributes of injected or infused preventive migraine medications: findings from a discrete choice experiment. Headache J. Head Face Pain63(4), 484–493 (2023).
  • Peres MFP , SilbersteinS , MoreiraFet al. Patients’ preference for migraine preventive therapy. Headache J. Head Face Pain47(4), 540–545 (2007).
  • Mitsikostas DD , BelesiotiI , ArvanitiCet al. Patients’ preferences for headache acute and preventive treatment. J. Headache Pain18, 1–8 (2017).
  • Gallagher RM , KunkelR. Migraine medication attributes important for patient compliance: concerns about side effects may delay treatment. Headache J. Head Face Pain43(1), 36–43 (2003).
  • Delussi M , VecchioE , LibroG , QuitadamoS , DeTommaso M. Failure of preventive treatments in migraine: an observational retrospective study in a tertiary headache center. BMC Neurol.20, 1–12 (2020).
  • Garza I , SwansonJW. Prophylaxis of migraine. Neuropsychiatr. Dis. Treat.2(3), 281–291 (2006).
  • Schwedt TJ , LiptonRB , AilaniJet al. Time course of efficacy of atogepant for the preventive treatment of migraine: results from the randomized, double-blind ADVANCE trial. Cephalalgia42(1), 3–11 (2022).
  • Nierenburg H , Stark-InbarA. Nerivio® remote electrical neuromodulation for acute treatment of chronic migraine. Pain Manag.12(3), 267–281 (2022).
  • Rapoport AM , LinT. Device profile of the Nerivio™ for acute migraine treatment: overview of its efficacy and safety. Expert Rev. Med. Devices16(12), 1017–1023 (2019).
  • Grosberg B , RabanyL , LinTet al. Safety and efficacy of remote electrical neuromodulation for the acute treatment of chronic migraine: an open-label study. Pain Rep.6(4), e966 (2021).
  • Nierenburg H , VieiraJR , LevNet al. Remote electrical neuromodulation for the acute treatment of migraine in patients with chronic migraine: an open-label pilot study. Pain Ther.9(2), 531–543 (2020).
  • Yarnitsky D , DodickDW , GrosbergBMet al. Remote electrical neuromodulation (REN) relieves acute migraine: a randomized, double-blind, placebo-controlled, multicenter trial. Headache59(8), 1240–1252 (2019).
  • Hershey AD , LinT , GruperYet al. Remote electrical neuromodulation for acute treatment of migraine in adolescents. Headache J. Head Face Pain61(2), 310–317 (2021).
  • Tepper SJ , RabanyL , CowanRPet al. Remote electrical neuromodulation for migraine prevention: a double-blind, randomized, placebo-controlled clinical trial. Headache J. Head Face Pain63(3), 377–389 (2023).
  • Croop R , LiptonRB , KudrowDet al. Oral rimegepant for preventive treatment of migraine: a phase 2/3, randomised, double-blind, placebo-controlled trial. Lancet397(10268), 51–60 (2021).
  • Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition. Cephalalgia38(1), 1–211 (2018).
  • Gonzalez JM , JohnsonFR , RunkenMC , PoulosCM. Evaluating migraineurs’ preferences for migraine treatment outcomes using a choice experiment. Headache J. Head Face Pain53(10), 1635–1650 (2013).
  • Mansfield C , GebbenDJ , SutphinJet al. Patient preferences for preventive migraine treatments: a discrete-choice experiment. Headache J. Head Face Pain59(5), 715–726 (2019).
  • Brandes JL , SaperJR , DiamondMet al. Topiramate for migraine prevention: a randomized controlled trial. JAMA291(8), 965–973 (2004).
  • Schoenen J , VandersmissenB , JeangetteSet al. Migraine prevention with a supraorbital transcutaneous stimulator a randomized controlled trial. Neurology80(8), 697–704 (2013).

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.